ArticleNature biomedical engineering2018
Efficacy and safety assessment of a TRAF6-targeted nanoimmunotherapy in atherosclerotic mice and non-human primates.
Erratum issuedOpen access · greenAbstract read
In one paragraph
Article in Nature biomedical engineering, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 79 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
79citing papers in PubMed, 1 pooled it
5.7field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
79 citing papers in PubMed, 1 synthesis or guideline pooled it, 125 citations in OpenAlex.
- A bibliometric analysis of immunotherapy for atherosclerosis: trends and hotspots prediction.Frontiers in immunology · 2024Pooled it
- Emerging biomedical and pharmaceutical strategies for the treatment of atherosclerosis: from conventional lipid-lowering therapy to nanomedicine.Journal of applied biomedicine · 2026Review
- Restoring immune homeostasis in atherosclerotic plaques via inorganic violet phosphorus nano-immunotherapy.Cell reports. Medicine · 2026Article
- Research progress on macrophage regulation of atherosclerosis.Frontiers in cardiovascular medicine · 2026Review
- How Advanced is Nanomedicine to Treat Atherosclerosis? A Comprehensive Review of the Literature.International journal of nanomedicine · 2026Review
- TRAF6 promotes pulmonary hypertension by enhancing K63-linked ubiquitination and activation of STAT3.Frontiers in pharmacology · 2026Article
- Radiolabeling lipoproteins to study and manage disease.European journal of nuclear medicine and molecular imaging · 2025Review
- A New Approach to the Diagnosis and Treatment of Cardiovascular Diseases.Pharmaceutics · 2025Review
- A programmable platelet theranostic platform for adaptive multi-stage delivery and synergistic immunotherapy in atherosclerosis.Nature communications · 2025Article
- Article
- CD40-TRAF6 inhibition suppresses cardiovascular inflammation, oxidative stress and functional complications in a mouse model of arterial hypertension.Redox biology · 2025Article
- Cardiovascular Disease and Cancer: A Dangerous Liaison.Arteriosclerosis, thrombosis, and vascular biology · 2025Review
- Dendritic cells immunotargeted therapy for atherosclerosis.Acta pharmaceutica Sinica. B · 2025Review
- Non-rodent Models of Atherosclerosis: Repurposing of Existing Drugs and Search for Novel Treatment Strategies.Current cardiology reviews · 2025Review
- Macrophage-Targeted Nanomedicine for the Treatment of Atherosclerosis.International journal of nanomedicine · 2025Review
- Article
- Polymersomes with splenic avidity target red pulp myeloid cells for cancer immunotherapy.Nature nanotechnology · 2024Article
- Trained immunity is regulated by T cell-induced CD40-TRAF6 signaling.Cell reports · 2024Article
- Resolvin D1 delivery to lesional macrophages using antioxidative black phosphorus nanosheets for atherosclerosis treatment.Nature nanotechnology · 2024Article
- Role of inflammatory signaling pathways involving the CD40-CD40L-TRAF cascade in diabetes and hypertension-insights from animal and human studies.Basic research in cardiology · 2024Article
19 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Erratum issued
Authors and funding
31 authors at 8 institutions in 4 countries.
Marnix LameijerTranslational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Tina BinderupCluster for Molecular Imaging and Department of Clinical Physiology, Nuclear Medicine and PET, Rigshospitalet and University of Copenhagen, Copenhagen, Denmark.
Mandy M T van LeentTranslational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Max L SendersTranslational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Francois FayTranslational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Joost MalkusTranslational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Brenda L Sanchez-GaytanTranslational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Abraham J P TeunissenTranslational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Nicolas KarakatsanisTranslational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID 0000-0001-7326-3053
Philip RobsonTranslational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Xianxiao ZhouDepartment of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Yuxiang YeCenter for Systems Biology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Gregory WojtkiewiczCenter for Systems Biology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.ORCID 0000-0002-3148-8411
Jun TangDepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0002-8285-5111
Tom T P SeijkensDepartment of Medical Biochemistry, Academic Medical Center, Amsterdam, The Netherlands.
Jeffrey KroonDepartment of Vascular Medicine, Amsterdam Cardiovascular Sciences, Academic Medical Center, Amsterdam, The Netherlands.ORCID 0000-0001-9983-6614
Erik S G StroesDepartment of Vascular Medicine, Amsterdam Cardiovascular Sciences, Academic Medical Center, Amsterdam, The Netherlands.
Andreas KjaerCluster for Molecular Imaging and Department of Clinical Physiology, Nuclear Medicine and PET, Rigshospitalet and University of Copenhagen, Copenhagen, Denmark.ORCID 0000-0002-2706-5547
Jordi OchandoImmunology Institute, Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Thomas ReinerDepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0002-7819-5480
Carlos Pérez-MedinaTranslational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Claudia CalcagnoTranslational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Edward A FisherDepartment of Medicine (Cardiology) and Cell Biology, Marc and Ruti Bell Program in Vascular Biology, NYU School of Medicine, New York, NY, USA.
Bin ZhangDepartment of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Ryan E TemelSaha Cardiovascular Research Center and Department of Pharmacology and Nutritional Sciences, University of Kentucky, Lexington, KY, USA.
Filip K SwirskiCenter for Systems Biology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Matthias NahrendorfCenter for Systems Biology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.ORCID 0000-0002-4021-1887
Zahi A FayadTranslational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Esther LutgensDepartment of Medical Biochemistry, Academic Medical Center, Amsterdam, The Netherlands.
Willem J M MulderTranslational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. willem.mulder@mssm.edu.
Raphaël DuivenvoordenTranslational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. r.duivenvoorden@amc.uva.nl.
Amsterdam UMC Location University of Amsterdam · NLImaging Center · USHarvard University · USIcahn School of Medicine at Mount Sinai · USMemorial Sloan Kettering Cancer Center · USUniversity of Copenhagen · DKNew York University · USUniversity of Kentucky · US
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4MTranslational imaging and nanomedicine in inflammatory atherosclerosisP01HL131478 · NHLBI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Zahi A. Fayad · 2017 to 2026
$24.3MMR/PET Imaging of coronary atherosclerosisR01HL071021 · NHLBI · MOUNT SINAI SCHOOL OF MEDICINE OF NYU · PI FAYAD, ZAHI A. · 2002 to 2019
$7.8MTheranostic HDL nanoparticles for inflammatory macrophages in atherosclerosisR01EB009638 · NIBIB · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI FAYAD, ZAHI A. · 2009 to 2016
$4.6MEffects of Anti-miR-33 on Atherosclerosis Regression and RCT in Nonhuman PrimatesR01HL111932 · NHLBI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI TEMEL, RYAN EUGENE · 2013 to 2017
$3.6MTRAF6 Nanoimmunotherapy to resolve plaque inflammationR01HL144072 · NHLBI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI FAYAD, ZAHI A. · 2018 to 2021
$3.3MPET/MRI to study nanotherapy in atherosclerosisR01HL125703 · NHLBI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI MULDER, WILLEM · 2015 to 2018
$2.4MAnti-inflammatory nanoparticle formulations to treat atherosclerosisR01HL118440 · NHLBI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI MULDER, WILLEM, NAHRENDORF, MATTHIAS · 2014 to 2017
$2.3MNCI NIH HHS P30 CA008748NHLBI NIH HHS P01 HL131478NHLBI NIH HHS R01 HL071021NHLBI NIH HHS R01 HL111932NHLBI NIH HHS R01 HL118440NHLBI NIH HHS R01 HL125703NHLBI NIH HHS R01 HL144072NIBIB NIH HHS R01 EB009638
Abstract
Macrophage accumulation in atherosclerosis is directly linked to the destabilization and rupture of plaque, causing acute atherothrombotic events. Circulating monocytes enter the plaque and differentiate into macrophages, where they are activated by CD4
Indexed as
AnimalsAtherosclerosisCD40 AntigensCD40 LigandDisease Models, AnimalFemaleImmunotherapyMacaca fascicularisMacrophagesMaleMiceMice, TransgenicMonocytesNanomedicineTissue DistributionTNF Receptor-Associated Factor 6CD40 AntigensCD40 LigandTNF Receptor-Associated Factor 6
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.